The joint venture plans to invest about ₹300 crore in Genome Valley Phase 4 over the next three years. The initiative is expected to create over 250 jobs, strengthening the country’s expertise in manufacturing isotopically labelled molecules used in pharmaceutical research, diagnostics, advanced electronics, and semiconductor applications.
“Stable isotopes and labelled molecules are essential tools for modern pharmaceutical research, diagnostics, and emerging electronics applications. The proposed facility will manufacture a wide range of stable isotope–labelled compounds that are critical for drug discovery, metabolic studies, diagnostics, and advanced materials research,” Shakthi M. Nagappan, CEO of Telangana Life Sciences, said here in a statement on Saturday.
“This investment will also help reduce India’s dependence on imports in this highly specialised segment of the life sciences and advanced materials industry,” he said.
Published on March 14, 2026